Cadrenal shares fall 12.11% after-hours as financial results show ongoing losses and cash balance raises capital concerns.

Cadrenal Therapeutics fell 12.11% in after-hour trading following the release of its fourth-quarter 2025 financial results and corporate update. The report showed a net loss of $3.0 million for the quarter, down from $4.2 million in the prior year, and disclosed that the company ended the quarter with only $4.0 million in cash. The update also highlighted the completion of the End-of-Phase 2 FDA meeting for CAD-1005, but did not include a near-term catalyst such as positive Phase 3 guidance or partnership announcements. Investors appeared concerned about the company’s limited liquidity and the lack of immediate regulatory clarity, leading to the sharp decline.